Therapeutic Solutions International Inc 的关键财务报表是什么?
TSOI 的关键财务比率是什么?
Therapeutic Solutions International Inc 的收入按细分市场或地理位置如何划分?
Therapeutic Solutions International Inc 是否盈利?
Therapeutic Solutions International Inc 有负债吗?
Therapeutic Solutions International Inc 的流通股有多少?
关键数据
前收盘价
$0.0001
开盘价
$0.0001
当日区间
$0.0001 - $0.0001
52周范围
$0 - $0.0004
交易量
262.5K
平均成交量
1.2M
每股收益(TTM)
-0.00
股息收益率
--
市值
$512.2K
什么是 TSOI?
Therapeutic Solutions International, Inc. engages in the provision of immune modulation for the treatment of several specific diseases. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The company has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. The company has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.